Tapestry Pharmaceuticals, Inc.

Napro Biotherapeutics, Inc.

Arbor Therapeutics, LLC

Other

University of Mississippi

Signpath Pharma, Inc.

Ironstone Separations, Inc.

Veiled Therapeutics LLC

James D McChesney

Jan J Zygmunt

John L Marshall

Gilles Hugues Tapolsky

Michael Kurman

Manuel R Modiano

David Lloyd Emerson

Madhavi C Chander

Mahesh Kumar Gundluru

Douglas L Rodenburg

James Ferrara

Sylesh Kumar Venkataraman

John T Henri

Igor Nikoulin

Herbert R Brinkman

Nicholas J Sisti

Xian Liang

Daniel Emil Levy

Annie Bouchard

Steve J Bannister

Saravanan Kappusamy

Mankil Jung

Allen Cohn

Tauseef Ahmed

John Kallikat Augustine

Mahmoud Ahmed ElSohly

Teruna J Siahaan

Hala N ElSohly

David E Emerson

Sterling K Ainsworth

Christine R Xu

Edward M Croom, Jr

Siead Zegar

Arba L Ager

Marilyn Bartlett

Dhammika N Nanayakkara

Michael S Alexander

Medhavi C Chander

David Baehr

John T Henry

The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

Biologically active taxane analogs and methods of treatment by oral administration

Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.

Taxane analogs for the treatment of brain cancer

The present invention includes compound having the following structural formula:

Cardiopathy-reducing phosphodiester lipids

The present invention includes compound having the following structural formula: 

The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents. 

Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubules at G2-M interface during mitosis but is not a substrate for MDR protein. In particular, the present application relates to the use of an orally effective abeo-taxane, alone or in combination with temozolomide or bevacizumab, for the treatment of brain cancer.

In one embodiment, the present application discloses compositions and methods of solubilizing pterostilbene or resveratrol, or mixture thereof in aqueous media.

Solubilization of pterostilbene and resveratrol for aqueous beverages

The present invention relates to a method for the treatment of cancer in a cancer patient. In particular, the invention provides a method for the treatment comprising administering a taxane compound to a cancer patient, wherein the taxane compound is made by a process comprising treating a first compound represented by either Formula G' or Formula M&#x2032;: with a second compound of generalized formula RRC(OCH)and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein Rand Rare each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; Ris an alkyl group, an olefinic group, or an aromatic group; Pis a hydroxyl protecting group; Pis H or an acid labile protecting group at the 7-O position; Ris H, alkyl group, olefinic or aromatic group; and Ris: H, alkyl group, olefinic or aromatic or is as defined in the specification.

9,10-&#x3b1;,&#x3b1;-OH-taxane analogs and methods for production thereof

In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.

Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation

Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G' or Formula M&#x2032;: with a second compound of generalized formula RRC(OCH)and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein Rand Rare each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; Ris an alkyl group, an olefinic group, or an aromatic group; Pis a hydroxyl protecting group; Pis H or an acid labile protecting group at the 7-O position; Ris H, alkyl group, olefinic or aromatic group; and Ris: H, alkyl group, olefinic or aromatic or is as defined in the specification.

The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.

Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents

Growing community of inventors

Etta, MS, United States of America

James D McChesney